Logo Volv Global
Contact
Volv Global’s advanced and proprietary machine learning technology for detection across disease spectrums

inTrigue

With inTrigue, our flagship AI/ML methodology, Volv Global transforms disease management and treatment at the individual patient level. 

We use high sensitivity, state-of-the-art machine learning technologies to detect digital biomarkers in human diseases, focussing on areas of significant unmet need or difficult-to-diagnose conditions. 

Smiling young woman in a casual outfit, black and white portrait
What is Volv Global inTrigue?

Truly personalised medicine

Harnessing the power of inTrigue, we don’t just find patients—we understand them. Our advanced machine learning models provide detailed patient profiles, capturing the nuances of each individual’s health journey. 

This deep profiling enables healthcare providers and researchers to tailor treatments and interventions with unprecedented precision. By focusing on personalised insights, we not only enhance the accuracy of diagnoses but also improve the overall effectiveness of care, leading to better health outcomes for patients. 

Unlock accurate
diagnosis

inTrigue uses machine learning to learn digital biomarkers for any human disease as well as developing robust prediction models for difficult-to-diagnose conditions, where there is significant unmet need.

Generate
real-world evidence

inTrigue generates data-driven insights longitudinally along the patient journey, enabling understanding of disease progression and establishing natural histories.

Personalised
healthcare

inTrigue enables precise patient-level insights for disease management, transforming disease management and treatment at the level of the individual, allowing a paradigm shift in targeting accuracy.

Reducing healthcare
cost / burden

inTrigue insights may optimise outcomes across the healthcare ecosystem, removing the economic cost of late or incorrect diagnoses which lead to ineffective treatment programmes, long-term care costs, and deteriorating health.

Young woman standing with an umbrella on a rainy night in the city, black and white photo

Insights at your fingertips

inVolv platform

inVolv is Volv Global’s secure platform for delivering actionable insights generated by inTrigue directly to partners and clients. It supports data-driven decision-making by providing tailored reporting and analytics for various stakeholders, in the form of interactive filters and visualisations such as charts and heatmaps.

inTrigue supports the development of new treatments

Impact across the product lifecycle

Portrait of an older man with a beard, resting his face on his hand, black and white photo

Volv Global started in rare and difficult-to-diagnose diseases

The challenge of rare diseases

Rare diseases manifest in less than one person among thousands. Doctors have less experience with them, and developers of therapies and payers have less patients to draw understanding from … leaving patients in a healthcare limbo.  

Depending on definitions of “rare,” over 300 million people – or 3.5-5.9% of the world population – suffer from 6,000-10,000 rare diseases. 

EURORDIS – Rare Diseases Europe

NORD – the National Organization for Rare Disorder

Patient resources

Navigating complexities

Beyond rare and difficult-to-diagnose diseases

With very small patient populations, developing a true understanding of rare disease prevalence, epidemiology, progression, patient journey and outcomes is a complex task. 

We had to bridge the diagnostic gap and create tailored machine learning algorithms to learn for themselves how to characterise and identify patients with disease. 

Limited treatment options

Thousands of rare diseases and only 5% have a treatment, leaving 95% unaddressed

Limited knowledge

For many of these diseases, there is little knowledge and a need to master the complex disease biology

Everyone is unique

Small, heterogeneous patient populations present challenges for clinical development

Pipeline herding

"Pipeline herding" means development efforts are unevenly distributed, leaving an unmet needs gap

Societal burden

Not treating rare diseases is costing more than people realise, and we need to reduce healthcare costs overall

Understanding patient phenomenology, across all diseases.

Volv Global’s suite of services

We find
more
patients

inTrigue helps clinicians to recognise undiagnosed and misdiagnosed patients by profiling patient cohorts by biomarkers, phenotypes, and other clinical information.

We detect
diseases at an
earlier stage​

inTrigue learns and models the patient journey, finding novel predictors that allow the detection of patients before the first symptoms appear.

We predict
patient
outcomes

inTrigue models patient outcomes to understand and segment patients by their needs for care.

We stratify
patient
cohorts

inTrigue makes sense of heterogeneous patient populations, clustering and differentiating cohorts into meaningful sub-groups.

Volv Global powers solutions across stakeholders

Impact across the product lifecycle​

Clinical
Development

inTrigue learns new biomarkers for diseases, enabling more accurate search and identification of patients for clinical trial planning and recruitment.

Value, Access
& HEOR

inTrigue analytics are a valuable resource for natural histories of diseases, and the generation of real-world evidence for regulatory approvals.

Medical
Affairs

inTrigue provides new insights into disease progression, outcomes and endpoints based on proprietary machine learning analytics on real-world evidence.

Commercial
Excellence

inTrigue offers patient and disease insights that enable accurate profiling of patients who will benefit the most from specific treatments.

Bridging technology and treatment

All about inTrigue

Volv Global’s proprietary methods can efficiently extract meaningful insights from sparse, unstructured, messy or inaccurate data in EHRs and claims records, to help identify patients at risk of complex diseases. 

The inTrigue methodology builds proprietary computational models using expert machine learning algorithms to detect biomarkers, phenotypes and other clinical features of patients in real-world, population-scale medical data databases such as electronic health and claims records.

Customised algorithms

inTrigue is customised for each project and learns from available data rather than existing knowledge or guidelines. Automated disease learning is carried out from first principles, producing a mathematical representation of the disease as a starting point in the inTrigue process.

High precision methodology

inTrigue produces accurate models and thereby more compelling evidence than other methods. The inTrigue methodology includes independent validation by disease experts and continuous refinement.

Patient privacy by design

Volv Global is a “no data” company. We do not work with identifiable patient data, we do not ingest data. We do not hold patient data, by design, relying on trustworthy data processors in different geographies.

Learn once, use everywhere

inTrigue works across the entire healthcare ecosystem from GPs to academic centres to data partners and EMR providers. inTrigue algorithms are designed to learn once; and can then be adapted for use across ontologies and systems.

Seamless integration

inTrigue can be integrated seamlessly with existing healthcare systems. As individual country systems and data are different, inTrigue learns the model in each country, adapting to differences in clinical thinking, language and data structure.

Talk to us

Ready to shape the future of healthcare? Let’s explore how our machine learning solutions can accelerate diagnoses, refine patient journeys, and drive meaningful impact for those who need it most. We value your ideas and expertise, reach out now to unlock new possibilities together.

Connect with our team

© Volv Global 2025

Youtube Linkedin
Logo Volv Global

How we help you

inTrigue

What we do

Insights

Meet Volv Global

inTrigue

Meet Volv Global